Follow us on Twitter
This page is updated frequently with new Histidine-related patents. Subscribe to the Histidine RSS feed to automatically get the update: related Histidine RSS feeds.
Subscribe to updates on this page: Histidine RSS
|| List of recent Histidine-related patents
|Particles and other substrates useful in protein purification and other applications|
The present invention generally relates to particles, including microgel particles, for purifying proteins and other species. In one aspect, the particles comprise a metal-chelating moiety, which may be distributed substantially evenly throughout the particle in certain embodiments.
|Yeast cell for the production of terpenes and uses thereof|
The present invention relates to a yeast cell, wherein said cell comprises a functional gene coding for soluble hydroxymethylglutaryl-coenzyme-a (hmg-coa) reductase; one or more gene(s) coding for steryl acyltransferase(s) in said cell are defective or deleted; and said cell is prototrophic for at least histidine, leucine or uracil. Moreover, the present invention relates to the use of said cell for the production of one or more terpene(s).
|Composition for long-acting peptide analogs|
The invention describes compositions of peptide analogs that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: a-(cm)x-peptide (seq id no: 76), wherein a is hydrophobic moiety or a metal binding moiety, e.g., a chemical group or moiety containing 1) an alkyl group having 6 to 36 carbon units, 2) a nitrilotriacetic acid group, 3) an imidodiacetic acid group, or 4) a moiety of formula (zyhisw)p (seq id no: 50), wherein z is any amino acid residue other than histidine, his is histidine, y is an integer from 0-6; w is an integer from 1-6; and p is an integer from 1-6; wherein if a has alkyl group with 6 to 36 carbon units x is greater than 0; and cm is a cleavable moiety consisting of glycine or alanine or lysine or arginine or n-arginine or n-lysine, wherein x is an integer between 0-6 and n may be any amino acid or none.
|Method for selective derivatization of oligohistidine sequence of recombinant proteins|
Methods and compositions for the selective derivatization of a oligohistidine-tagged recombinant protein. A modifying compound comprised of an imidazole reactive group, a linker, and a ligating group is contacted with the recombinant protein, and a cooperative bond forms between the ligating group and the oligohistidine tag in the presence of a metal cation, and a covalent bond forms between the imidazole reactive group and an imidazole ring of the oligohistidine tag followed by the concomitant separation of the imidazole reactive group from the linker.
|Reverse transcriptase having improved thermostability|
The present invention relates to a reverse transcriptase having improved thermostability, more precisely a mutant reverse transcriptase with improved thermostability by substitution of one or more amino acids selected from the group consisting of the 63rd glutamine (q63), the 264th lysine (k264), the 295th lysine (k295), the 306th threonine (t306), the 346th glutamic acid (e346), the 408th proline (p408), the 438th histidine (h438), and the 454th asparagin (n454) of the amino acid sequence of m-mlv originated reverse transcriptase represented by seq. Id.
|Nanoparticles containing ph-responsive peptide|
The present invention provides a nanoparticle and cell induction agent, capable of releasing a target substance in a weakly acidic ph environment. Specifically, the present invention provides a nanoparticle comprising a peptide and a particle-forming component, the particle-forming component forming a liposome or a micelle, the peptide having a sequence with 2 to 8 units starting with his (histidine) and ending with an acidic amino acid, wherein each of the units may be identical or different..
|Anti-pcsk9 antibodies with ph-dependent binding characteristics|
The present invention provides antibodies and antigen-binding fragments thereof that specifically bind proprotein convertase subtilisin/kexin-9 (pcsk9) with greater affinity at neutral ph than at acidic ph. The antibodies of the invention may possess one or more amino acid changes as compared to antibodies that do not exhibit ph-dependent binding properties.
|Polymeric conjugates and methods of preparing the same|
Methods of preparing polymer target conjugates which are substantially free of polymer attachment on the n-terminal of the targets are provided. Also provided are compositions comprising a plurality of polymer-polypeptide conjugates, said polymer-polypeptide conjugate comprising a polypeptide covalently attached to at least one polymer through an epsilon amino group of a lysine or a histidine found on the polypeptide and said conjugates containing less than 5% of the polymer-polypeptide conjugates having a polymer attached to the n-terminal of the polypeptide; and polymer target conjugates comprising a target moiety selected from the group consisting of polypeptides, proteins and the like having at least one polymer attached thereto at a site which is not the n-terminal of the target..
|Site-specific labeling of affinity tags in fusion proteins|
The present invention provides methods and fluorescent compounds that facilitate detecting and labeling of a fusion protein by being capable of selectively binding to an affinity tag. The fluorescent compounds have the general formula a(b)n, wherein a is a fluorophore, b is a binding domain that is a charged chemical moiety, a protein or fragment thereof and n is an integer from 1-6 with the proviso that the protein or fragment thereof not be an antibody or generated from an antibody.
The invention provides a pharmaceutical composition for oral administration of a pharmaceutically active agent to a subject, including the pharmaceutically active agent and an inhibitor of cyp3a4. Administration of the inhibitor and the pharmaceutically active agent reduces pre-systemic degradation of the pharmaceutically active agent by cyp3a4.
|Novel alkali-resistant variants of protein a and their use in affinity chromatography|
The present invention relates to immunoglobulin (ig)-binding proteins with alkali-resistance properties. In one embodiment, the present invention provides for a variant of an ig-binding protein, the variant comprising the ig-binding protein having at least one asparagine residue substituted with a histidine, a serine, an aspartic acid or a threonine residue.
|Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same|
A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of ph dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses human immunoglobulin light chain variable domains derived from a limited repertoire of human immunoglobulin light chain variable gene segments that comprise histidine modifications in their germline sequence.
|Sirna compositions and methods for treatment of hpv and other infections|
The invention provides sirna compositions that (1) interfere with viral replication of human papillomavirus (hpv), herpes simplex virus (hsv), and human immunodeficiency virus (hiv) in mucosal tissues, such as genital tissues, and (2) treat fungal infections. The compositions include sirna molecules that target hpv, complexed with a dendrimer that treats and prevents genital herpes (hsv) and hiv.
|Affinity chromatography matrix|
The present invention relates to a method of separating one or more immunoglobulin containing proteins from a liquid. The method includes first contacting the liquid with a separation matrix comprising ligands immobilised to a support; allowing the immunoglobulin containing proteins to adsorb to the matrix by interaction with the ligands; followed by an optional step of washing the matrix containing the immunoglobulin containing proteins adsorbed thereon; and recovering said immunoglobulin containing proteins by contacting the matrix with an eluent which releases the proteins.
|Use of single amino acids at low concentrations for influencing the life processes of crops|
This invention relates to the use of a composition in low doses containing single l-amino acids, including their precursors and biologically still active metabolites, to influence the life processes of plants, such as their growth, whereby the total amount of single l-amino acids when applying the composition is at least 0.5 g/ha and at most 250 g/ha, and wherein the l-amino acids are selected from the group of glutamine, asparagine, aspartic acid, histidine, lysine, and combinations thereof with each other and/or with arginine and/or with glutamic acid.. .
|Tooth bleaching catalytic and application thereof|
A method for forming a tooth bleaching catalytic is provided, wherein the method comprises steps as follows: firstly a plurality of histidine-functionalized mesoporous silica nano-particles (msns) is provided. Subsequently, the histidine-functionalized msns are condensating with a plurality of metal ions..
|Amadoriase having altered substrate specificity|
This invention provides an amadoriase having high substrate specificity to fructosyl valyl histidine. Such amadoriase comprises substitution of one or more amino acid residues at positions corresponding to amino acids selected from the group consisting of position 98, position 259, position 154, position 125, position 261, position 263, position 106, position 103, position 355, position 96, position 66, position 67, position 70, position 100, position 110, position 113, position 114, and position 156 in the amadoriase derived from the genus coniochaeta.
|Methods and compositions for increasing the anaerobic working capacity in tissues|
Provided are compositions comprising beta-alanylhistidine peptides and/or beta-alanines, and methods for administering these peptides and amino acids. In one aspect, the compositions and methods cause an increase in the blood plasma concentrations of beta-alanine and/or creatine..
The present invention relates to the phosphohistidine analogs of the present invention which of the formula (i) and the hapten containing the residue of same. It also relates to the hapten conjugated to a carrier molecule and the isolated antibodies raised against the immunogens, said antibodies recognizing polypeptide containing a phosphorylated histidine or the phosphotriazole residue but it does not recognize an amino acid or polypeptide that is not phosphorylated or a polypeptide which is phosphorylated on amino acids other than histidine but not on histidine..
|Non-human animals expressing ph-sensitive immunoglobulin sequences|
Genetically modified non-human animals are provided that express an immunoglobulin variable domain that comprises at least one histidine, wherein the at least one histidine is encoded by a substitution of a non-histidine codon in the germline of the animal with a hisidine codon, or the insertion of a histidine codon in a germline immunoglobulin nucleic acid sequence. Immunoglobulin genes comprising histidines in one or more cdrs, in an n-terminal region, and or in a loop 4 region are also provided.
|Mice that produce antigen-binding proteins with ph-dependent binding characteristics|
Genetically modified non-human animals are provided that comprise an immunoglobulin heavy chain locus comprising an unrearranged human heavy chain variable region nucleotide sequence comprising an addition of at least one histidine codon or a substitution of at least one endogenous non-histidine codon with a histidine codon. Compositions and methods for making the genetically modified non-human animals as described herein are provided.
|Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same|
A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of ph dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses a single light chain variable domain derived from a single rearranged light chain variable region gene in the germline of the non-human animal, wherein the single rearranged light chain variable region gene comprises a substitution of at least one non-histidine encoding codon with a histidine encoding codon.
|Fusion protein comprising small heat shock protein, cage protein formed thereby, and novel use thereof|
The present invention relates to a fusion protein comprising small heat shock protein, a cage protein formed thereby, and novel use thereof, more particularly, a fusion protein comprising a small heat shock protein, a recognition site of a protease, and a histidine polymer, wherein the recognition site and the histidine polymer are sequentially linked to a carboxyl terminal of the small heat shock protein, a cage protein formed thereby, and novel use thereof. The fusion protein of the present invention, and a cage protein formed by the self-assembly properties of the fusion protein are not cytotoxic, and emits a fluorescence signal of about 20 to about 50 times higher comparing to a single peptide for the conventional molecular imaging, per unit protein.
|Subcutaneous anti-her2 antibody formulations and uses thereof|
The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-her2 antibody, such as e.g. Trastuzumab (herceptin™), pertuzumab or t-dm1, or a mixture of such antibody molecules for subcutaneous injection.
|Nucleic acid aptamers against plasmodium lactate dehydrogenase and histidine-rich protein ii and uses thereof for malaria diagnosis|
The present invention provides nucleic acid aptamers that bind to plasmodium proteins lactate dehydrogenase and histidine-rich protein ii, and uses thereof for the diagnosis of malaria. Aptamers against histidine-rich protein ii may be used to detect the presence of plasmodium species in general, whereas aptamers against lactate dehydrogenase can be used to specifically detect plasmodium falciparum..
|Method for immobilizing a protein on self-assembled monolayer|
One molecule of the amino acid selected from the five kinds of amino acids consisting of cysteine, lysine, histidine, phenylalanine, and glycine is interposed between a self-assembled monolayer and a molecule of a protein. A method for immobilizing an protein on a self-assembled monolayer includes the following steps (a) and (b) in this order: a step (a) of preparing a substrate including one molecule of an amino acid and the self-assembled monolayer and a step (b) of supplying the protein to the substrate to form a peptide bond represented by a predetermined chemical formula as a result of reaction between the carboxyl group of the one molecular of the amino acid and the amino group of the protein..
|System and method for identifying complex patterns of amino acids|
A method and system are disclosed for identifying and/or locating complex patterns in an amino acid sequence stored in a computer file or database. According to an aspect of the present invention, techniques are provided to facilitate queries of protein databases.
|Methods and compositions related to immunizing against staphylococcal lung diseases and conditions|
Embodiments of the invention include methods and compositions useful in a vaccination strategy capable of neutralizing hla to provide immunoprotection against s. Aureus pneumonia.
This disclosure relates to immunogenic compositions comprising an isolated immunogenic s. Pneumoniae pcpa polypeptide and at least one additional antigen (such as for example, an isolated immunogenic s.
|Metamaterial optical elements self-assembled on protein scaffolds|
Protein scaffolds from tobacco mosaic virus coat protein modified to incorporate polyhistidine can bind to a metal or a dye while having improved self-assembly characteristics. The scaffold can take the form of tubes or disks, and can further be formed into dual plasmonic ring resonators.
|Interfering rna delivery system and uses thereof|
The invention provides a delivery system comprising a cell penetrating peptide, 10 histidines, and an interfering rna molecule. The system can be used for delivering interfering rna molecules into a cell in vivo or in vitro.
|C-terminal modification of polypeptides|
The invention relates to a mutated trypsin comprising an amino acid substitution both at position k60 and d189, and at least one more amino acid substitution by histidine at position n143 or position e151. Such trypsin mutant has a preferred cleavage site comprising the amino acids xaa1-xaa2-his, wherein xaa1 is l, y or f and xaa2 is r or k.
|Template-directed assembly of receptor signaling complexes|
Transmembrane receptors in the signaling pathways of bacterial chemotaxis systems influence cell motility by forming noncovalent complexes with the cytoplasmic signaling proteins to regulate their activity. The requirements for receptor-mediated activation of chea, the principal kinase of the escherichia coli chemotaxis signaling pathway, can be demonstrated using self-assembled clusters of a receptor fragment (cf) derived from the cytoplasmic domain of the aspartate receptor, tar.
|Mutant polyhydroxyalkanoic acid synthase gene and method for producing aliphatic polyester using the same|
A substitution mutation that improves polymerization activity of a polyhydroxyalkanoic acid synthase is identified. At least 1 amino acid residue selected from the group consisting of a histidine residue at position 17, a proline residue at position 71, a valine residue at position 131, a methionine residue at position 205, a leucine residue at position 230, and a proline residue at position 239 of a polyhydroxyalkanoic acid synthase derived from alcanivorax borkumensis is subjected to substitution mutation with another amino acid..
|Production and use of bacterial histamine|
A method is provided of selecting specific probiotic lactic acid bacteria producing histamine and the use of such strains for beneficial effects for mammals. The method includes selecting a lactic acid bacterial strain for use in the local production of histamine in a mammal, and further comprises screening bacteria for the presence of an.
|Histidine rich protein-2 diagnostic test for cerebral malaria|
The present inventions relate to accurately identifying a subset of patients within a larger group with malarial parasitemia. In particular, the present inventions provide compositions and methods comprising a malarial protein, histidine rich pro-tein-2 (hrp-2) for determining the general severity of a malarial infection in patients.
|Novel peptide and use thereof|
The present invention provides a peptide represented by formula (i) of x1-leu-x2-leu-x3 wherein x1 represents glu or asp, x2 represents his, lys or arg, x3 represents asp or glu, with glu, asp, leu, his, lys and arg being respectively glutamic acid, aspartic acid, leucine, histidine, lysine and arginine; or a pharmaceutically acceptable salt thereof; a composition for the treatment or prevention of at least one selected from cartilage damage and arthritis, containing the same peptide or a pharmaceutically acceptable salt thereof as an active ingredient; and a composition containing the same peptide or a pharmaceutically acceptable salt thereof and tgfβ1. The above-mentioned peptide or a pharmaceutically acceptable salt thereof is effective for the treatment and/or prevention of cartilage damage and/or arthritis and is capable of exhibiting effects of the regeneration of cartilage tissue, the inhibition of the expression of cartilage tissue matrix degrading enzyme and/or the inhibition of cartilage tissue ossification..
|High protein supplement|
The present disclosure relates to high protein dietary supplements for treating various symptoms and diseases associated with protein deficiency including weight gain, obesity, catabolic diseases, fibromyalgia, anxiety reactions, posttraumatic stress and chronic fatigue syndrome. Embodiments of dietary supplements comprise combinations of proteins, essential and semi-essential amino acids including l-lysine, l-arginine, and/or l-histidine..
|Stabalized glycosaminoglycan preparations and related methods|
Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl cellulose and carboxyethyl cellulose, hydroxyl ethyl starch, hydroxyl propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polylysine, polyhistidine, polyhydroxy proline, poly ornithine, polyvinyl pyrolidone, polyvinyl alcohol, chitosan, etc.) and iii) long chain nitrogen containing polymers (e.g., polylysine, polyvinylpyrrolidone, and polyvinyl alcohol). The invention also includes methods for using such compositions (e.g., as substance delivery materials, tissue fillers or bulking agents, as moistening or hydrating agents, etc.).
|Use of chromium histidinate for treatment of cardiometabolic disorders|
Provided herein are methods for treating, preventing, and improving conditions associated with cardiometabolic syndrome, by identifying a subject in need of treatment, prevention, or improvement of a condition associated with cardiometabolic syndrome, and providing a therapeutically effective amount of a composition comprising chromium and histidine, chromium histidinate complexes, or combinations thereof, to the individual.. .
|Process and method for broad spectrum amino acid challenged urinary organic acids|
Discloses is a process for detecting and evaluating metabolic disturbances and specific nutrient insufficiencies within an individual. The bio-chemical pathways of the individual are challenged by consuming an oral amino acid supplement prior to urine sample collection.
|Long-acting insulin analogue preparations in soluble and crystalline forms|
A pharmaceutical formulation comprises an insulin analogue or a physiologically acceptable salt thereof, wherein the insulin analogue or a physiologically acceptable salt thereof contains an insulin a-chain sequence that contains paired histidine substitutions at a4 and a8, and optionally a substitution at a21. The formulation further contains a pharmaceutically acceptable buffer containing at least about 4 zinc ions per 6 insulin analogue molecules.
The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain ii of her2 (for example, pertuzumab), and a formulation comprising an antibody that binds to dr5 (for example, apomab).. .
|Hydrophobic interaction chromatography method|
Herein is reported a method for purifying a polypeptide comprising a histidine-tag comprising the steps of i) applying a solution comprising the polypeptide with a histidine-tag to a hydrophobic interaction chromatography material, and ii) recovering the polypeptide comprising a histidine-tag with a solution comprising imidazole or an imidazole-derivative and thereby purifying the polypeptide comprising a histidine-tag, wherein the solution comprising the polypeptide applied to the hydrophobic interaction chromatography material is free of imidazole or an imidazole-derivative and the polypeptide adsorbed to the hydrophobic interaction chromatography material is recovered with a solution comprising imidazole or an imidazole-derivative.. .
|Methods and coatings for treating biofilms|
A method of treating, reducing, or inhibiting biofilm formation by bacteria, the method comprising: contacting an article with a composition comprising an effective amount of a d-amino acid, said composition being essentially free of the corresponding l-amino acid, thereby treating, reducing or inhibiting formation of the biofilm, wherein the d-amino acid is selected from the group consisting of d-alanine, d-cysteine, d-aspartic acid, d-glutamic acid, d-histidine, d-isoleucine, d-lysine, d-leucine, d-asparagine, d-proline, d-glutamine, d-arginine, d-serine, d-threonine, d-valine, d-tryptophan, d-tyrosine, and a combination thereof.. .
|Fertilization prediction and promotion|
The outcome of an in vitro fertilization (ivf) of a woman in terms of chances of successful pregnancy or the fertility status of a woman is predicted based on nucleotide analysis of the histidine-rich glycoprotein (hrg) gene or protein analysis of hrg. The proline isoform of hrg or an amino acid fragment thereof can further be used to increases the success of pregnancy of a woman..
|Glp-1 analogues and derivatives|
The invention relates to a glp-1 analogue which comprises a histidine (h) residue at a position corresponding to position 31 of glp-1 (7-37) (seq id no: 1), a glutamine (q) residue at a position corresponding to position 34 of glp-1 (7-37) (seq id no: 1), and a maximum of ten amino acid modifications as compared to glp-1 (7-37) (seq id no: 1); wherein the h residue is designated h31, and the q residue is designated q34; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to derivatives thereof, as well as the pharmaceutical use of these analogues and derivatives, for example in the treatment and/or prevention of all forms of diabetes and related diseases.
|Amyloid precursor protein e2 domain and uses thereof|
Members of the amyloid precursor protein family (app molecules) and their neurotoxic cleavage product aβ are key players in the development of alzheimer's disease (ad). Proteolytic processing of app molecules is influenced by metal ions, protein ligands and its oligomerization state.
|Method for chemical mechanical polishing copper|
A method for chemical mechanical polishing of a copper substrate, is provided, comprising: providing a copper substrate; providing slurry composition comprising, as initial components: water; 0.1 to 20 wt % abrasive; 0.01 to 15 wt % complexing agent; 0.02 to 5 wt % inhibitor; 0.01 to 5 wt % phosphorus containing compound; 0.001 to 3 wt % polyvinyl pyrrolidone; >0.1 to 1 wt % histidine; >0.1 to 1 wt % guanidine; optional oxidizing agent; optional leveling agent; optional biocide; and, optional ph adjusting agent; wherein the slurry composition provided has ph of 9 to 11; providing a chemical mechanical polishing pad with a polishing surface; dispensing the slimy composition onto the polishing surface at or near the interface between the polishing surface and the substrate; and, creating dynamic contact at an interface between the polishing surface and the substrate with a down force of 0.69 to 34.5 kpa; wherein the substrate is polished.. .
|Filler for affinity chromatography and method for isolating immunoglobulin|
Wherein r represents an amino acid sequence consisting of 4 to 300 amino acid residues containing a region consisting of 4 to 20 contiguous histidine residues; and r2 represents an amino acid sequence capable of binding to immunoglobulin, the amino acid sequence consisting of 50 to 500 amino acid residues containing z domain of protein a or a fragment thereof, or a variant thereof, provided that the r binds to c-terminus or n-terminus of the r2.. .
|Functionalization and purification of molecules by reversible group exchange|
Embodiments of the present disclosure include methods and compositions for functionalizing molecules, such as oligonucleotides, with functional groups, including polyhistidine tags useful in affinity methods. Some embodiments include methods for modifying and purifying complex mixtures of molecules by exchange of functional tags..
|Stabilized antibody-containing liquid formulations|
The present inventors discovered that a significant stabilization effect was achieved by using an acidic amino acid, aspartic acid or glutamic acid as a counter ion species in histidine buffer or tris(hydroxymethyl)aminomethane, specifically by using histidine-aspartate buffer or histidine-glutamate buffer, or tris(hydroxymethyl)aminomethane-aspartate or tris(hydroxymethyl)aminomethane-glutamate as a buffer. The present inventors also discovered that a significant stabilization effect was achieved by using an acidic amino acid, aspartic acid or glutamic acid, as a counter ion species to a basic amino acid such as arginine, specifically by using arginine-aspartate or arginine-glutamate..
|Production and use of bacterial histamine|
A method is provided of selecting specific probiotic lactic acid bacteria producing histamine and the use of such strains for beneficial effects for mammals. The method includes selecting a lactic acid bacterial strain for use in the local production of histamine in a mammal, and further comprises screening bacteria for the presence of an active histidine operon and selecting a strain which has an active histidine operon and is capable of producing histamine.
Popular terms: [SEARCH]
Histidine topics: Amino Acid, Amino Acids, Genetically, Antibodies, Immunoglobulin, Polypeptide, Nucleic Acid, Pertuzumab, Trastuzumab, Mesoporous Silica, Hemoglobin, Specificity, Carrier Molecule, Blood Plasma, Recombinant
Follow us on Twitter
This listing is a sample listing of patents related to Histidine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Histidine with additional patents listed. Browse our RSS directory or Search for other possible listings.